| 國立成功大學 |
2024-06-1 |
Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC): Subgroup analysis from TROPION-Lung02
|
Levy;Philip, Benjamin;Paz-Ares;Luis, G.;Su;Wu-Chou;Herbert;Scott, M.;Yang;Tsung-Ying;Tolcher;Anthony, W.;Lou;Yanyan;Zenke;Yoshitaka;Cortinovis;Luigi, Diego;Felip;Enriqueta;Domine;Manuel;Sr;Leventakos;Konstantinos;Calvo;Emiliano;Horiike;Atsushi;Pan;Edward;Lin;Daisy;Jia;Xiaoyu;Basak;Priyanka;Chisamore;Jon, Michael;Goto;Yasushi |
| 國立成功大學 |
2024-06-1 |
Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced/metastatic non-small cell lung cancer (a/m NSCLC) with actionable genomic alterations (AGA): Results from TROPION-Lung05
|
Lisberg;Aaron;Ahn;Myung-Ju;Kitazono;Satoru;Cho;Chul, Byoung;Blumenschein;George, R.;Shum;Elaine;Pons-Tostivint;Elvire;Goto;Yasushi;Yoh;Kiyotaka;Paz-Ares;Luis, G.;Heist;Suk, Rebecca;Baas;Paul;Planchard;David;Perol;Maurice;Felip;Enriqueta;Su;Wu-Chou;Zebger-Gong;Hong;Lan;Lan;Liu;Chelsea;Sands;Jacob |
| 國立成功大學 |
2024-06-01 |
Efficacy and safety of erdafitinib in patients with advanced or metastatic cholangiocarcinoma and FGFR alterations: Pooled analysis of RAGNAR and LUC2001 studies.
|
Pant;Shubham;Park;Oh, Joon;Su;Wu-Chou;Schuler;Martin, H.;Loriot;Yohann;Iyer;Gopa;Doi;Toshihiko;Qin;Shukui;Tabernero;Josep;Prenen;Hans;Folprecht;Gunnar;Winter;Helen;Molin, Dal;Zibetti, Graziela;Sweiti;Hussein;Najmi;Saltanat;Hammond;Constance;Liao;Huimin;Thomas;Shibu;Triantos;Spyros;Feng;Yin-Hsun |
| 國立成功大學 |
2024-05-22 |
IL-33/NF-κB/ST2L/Rab37 positive-feedback loop promotes M2 macrophage to limit chemotherapeutic efficacy in lung cancer
|
Yang;You-En;Hu;Meng-Hsuan;Zeng;Yen-Chen;Tseng;Yau-Lin;Chen;Ying-Yung;Su;Wu-Chou;Chang;Chih-Peng;Wang;Yi-Ching |
| 國立成功大學 |
2024-02-07 |
Rab37 mediates trafficking and membrane presentation of PD-1 to sustain T cell exhaustion in lung cancer
|
Kuo;Wan-Ting;Kuo;I-Ying;Hsieh;Hung-Chia;Wu;Ssu-Ting;Su;Wu-Chou;Wang;Yi-Ching |
| 國立成功大學 |
2024-02 |
Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study
|
Chang;Gee-Chen;Chiu;Chao-Hua;Yu;Chong-Jen;Chang;Yeun-Chung;Chang;Ya-Hsuan;Hsu;Kuo-Hsuan;Wu;Yu-Chung;Chen;Chih-Yi;Hsu;Hsian-He;Wu;Ming-Ting;Yang;Cheng-Ta;Chong;Inn-Wen;Lin;Yu-Ching;Hsia;Te-Chun;Lin;Meng-Chih;Su;Wu-Chou;Lin;Chih-Bin;Lee;Kang-Yun;Wei;Yu-Feng;Lan;Gong-Yau;Chan;Wing, P.;Wang;Kao-Lun;Wu;Mei-Han;Tsai;Hao-Hung;Chian;Chih-Feng;Lai;Ruay-Sheng;Shih;Jin-Yuan;Wang;Chi-Liang;Hsu;Jui-Sheng;Chen;Kun-Chieh;Chen;Chun-Ku;Hsia;Jiun-Yi;Peng;Chung-Kan;Tang;En-Kuei;Hsu;Chia-Lin;Chou;Teh-Ying;Shen;Wei-Chih;Tsai;Ying-Huang;Tsai;Chun-Ming;Chen;Yuh-Min;Lee;Yu-Chin;Chen;Hsuan-Yu;Yu;Sung-Liang;Chen;Chien-Jen;Wan;Yung-Liang;Hsiung;Agnes, Chao;Yang;Pan-Chyr |
| 國立成功大學 |
2024-02 |
TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
|
Atmaca;Akin;Paz-Ares;Luis;Ahn;Myung-Ju;Lisberg;Aaron;Kitazono;Satoru;Cho;Chul, Byoung;Blumenschein;George;Jr;Shum;Elaine;Tostivint;Pons, Elvire;Goto;Yasushi;Yoh;Kiyotaka;Heist;Rebecca;Baas;Paul;Planchard;David;Perol;Maurice;Felip;Enriqueta;Su;Wu-Chou;Zebger-Gong;Hong;Lan;Lan;Liu;Chelsea;Sands;Jacob;Reinmuth;Niels |
| 國立成功大學 |
2024-01 |
Clinical practice consensus for the diagnosis and management of melanoma in Taiwan
|
Wu;Chiao-En;Liao;Yi-Hua;Wu;Cheng-Lin;Yen;Ruoh-Fang;Lin;Chia-Chi;Yang;Muh-Hwa;Yen;Chueh-Chuan;Su;Wu-Chou;Yen;Chia-Jui;Chang;Yi-Fang;Wu;Ming-Fang;Yang;Youngsen;Lin;Chen-Yuan;Yang;Wen-Chi;Wang;Hui-Ching;Li;Cheng-Yuan;Ho;Yin-Yu;Chang;Yao-Yu;Wu;Chieh-Shan;Hsu;Hsiu-Cheng;Chen;Kuang-Hua;Huang;Yenlin;Chen;Chih-Jung;Chuang;Pei-Ju;Lai;Yung-Chi;Huang;Yu-Yi;Tseng;Neng-Chuan;Huang;Yi-Ting;Chu;Chia-Yu;Chang;John, Wen-Cheng |
| 國立成功大學 |
2023-12 |
Clinical implications of PNA-sequencing as a complementary test for EGFR mutation analysis in human lung cancer
|
Chen;Yi-Lin;Lin;Chien-Chung;Yu;Yu-Ting;Chen;Wan-Li;Yang;Shu-Ching;Huang;Wenya;Su;Wu-Chou;Chow;Nan-Haw;Ho;Chung-Liang |
| 國立成功大學 |
2023-11-2 |
Distinct Features of Plasma Ultrashort Single-Stranded Cell-Free DNA as Biomarkers for Lung Cancer Detection
|
Cheng;Jordan;Swarup;Neeti;Li;Feng;Kordi;Misagh;Lin;Chien-Chung;Yang;Szu-Chun;Huang;Wei-Lun;Aziz;Mohammad;Kim;Yong;Chia;David;Yeh;Yu-Min;Wei;Fang;Zheng;David;Zhang;Liying;Pellegrini;Matteo;Su;Wu-Chou;Wong;David, T. W. |
| 國立成功大學 |
2023-06-23 |
Concise nanotherapeutic modality for cancer involving graphene oxide dots in conjunction with ascorbic acid
|
Shih;Chun-Yan;Wang;Pei-Ting;Chung;Wei-Pang;Wang;Wen-Hsiu;Chiang;I-Ting;Su;Wu-Chou;Huang;Wei-Lun;Teng;Hsisheng |
| 國立成功大學 |
2023-03-9 |
Effect of BIM expression on the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs
|
Chu;Chang-Yao;Lin;Chien-Yu;Lin;Chien-Chung;Li;Chien-Feng;Wu;Shang-Yin;Tsai;Jeng-Shiuan;Yang;Szu-Chun;Chen;Chian-Wei;Lin;Chia-Yin;Chang;Chao-Chun;Yen;Yi-Ting;Tseng;Yau-Lin;Su;Po-Lan;Su;Wu-Chou |
| 國立成功大學 |
2022-11 |
Pembrolizumab and Chemotherapy Combination Prolonged Progression-Free Survival in Patients with NSCLC with High PD-L1 Expression and Low Neutrophil-to-Lymphocyte Ratio
|
Tsai;Jeng-Shiuan;Wei;Sheng-Huan;Chen;Chian-Wei;Yang;Szu-Chun;Tseng;Yau-Lin;Su;Po-Lan;Lin;Chien-Chung;Su;Wu-Chou |
| 國立成功大學 |
2022-08-11 |
Iron oxide@chlorophyll clustered nanoparticles eliminate bladder cancer by photodynamic immunotherapy-initiated ferroptosis and immunostimulation
|
Chin;Yu-Cheng;Yang;Li-Xing;Hsu;Fei-Ting;Hsu;Che-Wei;Chang;Te-Wei;Chen;Hsi-Ying;Chen;Linda, Yen-Chien;Chia;Chun, Zi;Hung;Chun-Hua;Su;Wu-Chou;Chiu;Yi-Chun;Huang;Chih-Chia;Liao;Mei-Yi |
| 國立成功大學 |
2022-08 |
Development of a cancer cells self-activating and miR-125a-5p expressing poly-pharmacological nanodrug for cancer treatment
|
Chang;Yung-Chieh;Shieh;Min-Chieh;Chang;Yen-Hsuan;Huang;Wei-Lun;Su;Wu-Chou;Cheng;Fong-Yu;Cheung;Antonio, Chun Hei |
| 國立成功大學 |
2022-05-20 |
Economic Analysis of Tissue-First, Plasma-First, and Complementary NGS Approaches for Treatment-Naive Metastatic Lung Adenocarcinoma
|
Yang;Szu-Chun;Lin;Chien-Chung;Chen;Yi-Lin;Su;Wu-Chou |
| 國立成功大學 |
2022-02-28 |
The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapy
|
Su;Po-Lan;Chen;Jung-Yueh;Chu;Chang-Yao;Chen;Yi-Lin;Chen;Wan-Li;Lin;Kuan-Yu;Ho;Chung-Liang;Tsai;Jeng-Shiuan;Yang;Szu-Chun;Chen;Chian-Wei;Wu;Yi-Lin;Tseng;Yau-Lin;Chang;Chao-Chun;Yen;Yi-Ting;Lin;Chia-Ying;Lin;Chien-Chung;Su;Wu-Chou |
| 國立成功大學 |
2022-01-7 |
FTY720 in resistant human epidermal growth factor receptor 2-positive breast cancer
|
Chung;Wei-Pang;Huang;Wei-Lun;Liao;Wei-An;Hung;Chun-Hua;Chiang;Chi-Wu;Cheung;Antonio, Chun Hei;Su;Wu-Chou |
| 國立成功大學 |
2022-01 |
Improved survival in patients with unresectable stage III EGFR-mutant adenocarcinoma with upfront EGFR-tyrosine kinase inhibitors
|
Wang;Sheng-Yuan;Lai;Ching-Han;Chen;Chian-Wei;Yang;Szu-Chun;Chang;Chao-Chun;Lin;Chia-Ying;Yen;Yi-Ting;Tseng;Yau-Lin;Su;Po-Lan;Lin;Chien-Chung;Su;Wu-Chou |
| 國立成功大學 |
2022 |
PI3K inhibitors in trastuzumab-resistant HER2-positive breast cancer cells with PI3K pathway alterations
|
Chung;Wei-Pang;Huang;Wei-Lun;Lee;Chun-Hui;Hsu;Hui-Ping;Huang;Wan-Ling;Liu;You-Yu;Su;Wu-Chou |
| 國立成功大學 |
2022 |
Targeting protumor factor chitinase-3-like-1 secreted by Rab37 vesicles for cancer immunotherapy
|
Yang;Pei-Shan;Yu;Min-Hua;Hou;Ya-Chin;Chang;Chih-Peng;Lin;Shao-Chieh;Kuo;I-Ying;Su;Pei-Chia;Cheng;Hung-Chi;Su;Wu-Chou;Shan;Yan-Shen;Wang;Yi-Ching |
| 國立成功大學 |
2021-12 |
Association between Altered Oncogenic Signaling Pathways and Overall Survival of Patients with Metastatic Colorectal Cancer
|
Huang;Yi-Hsuan;Lin;Peng-Chan;Su;Wu-Chou;Chan;Ren-Hao;Chen;Po-Chuan;Lin;Bo-Wen;Shen;Meng-Ru;Chen;Shang-Hung;Yeh;Yu-Min |
| 國立成功大學 |
2021-11 |
CD40 Pathway and IL-2 Expression Mediate the Differential Outcome of Colorectal Cancer Patients with Different CSF1R c.1085 Genotypes
|
Yeh;Yu-Min;Lin;Peng-Chan;Su;Wu-Chou;Shen;Meng-Ru |
| 國立成功大學 |
2021-09-24 |
Development of a novel ALK rearrangement screening test for non-small cell lung cancers
|
Chen;Yi-Lin;Chen;Wan-Li;Cheng;Yi-Chia;Lin;Ming-Ching;Yang;Shu-Ching;Tsai;Hung-Wen;Lin;Chien-Chung;Su;Wu-Chou;Chow;Nan-Haw;Ho;Chung-Liang |
| 國立成功大學 |
2021-09 |
EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysis
|
Tsai;Jeng-Shiuan;Su;Po-Lan;Yang;Szu-Chun;Chang;Chao-Chun;Lin;Chia-Ying;Yen;Yi-Ting;Tseng;Yau-Lin;Lai;Wu-Wei;Lin;Chien-Chung;Su;Wu-Chou |
